M. Dwyer

发表

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

E. Lees, T. Fischmann, P. Kirschmeier, 2010, Molecular Cancer Therapeutics.

linical Development aciclib ( SCH 727965 ) , a Novel and Potent Ther lin-Dependent Kinase Inhibitor

Parry, E. Lees, P. Kirschmeier, 2010 .

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

E. Lees, T. Fischmann, P. Kirschmeier, 2010, ACS medicinal chemistry letters.

Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.

T. Fischmann, T. Guzi, K. Paruch, 2013, Bioorganic & medicinal chemistry letters.

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.

Rebecca T. Ruck, E. Asante-Appiah, Kung-I Feng, 2017, Journal of medicinal chemistry.

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.

E. Asante-Appiah, M. Dwyer, A. Nomeir, 2018, Bioorganic & medicinal chemistry letters.

Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.

M. Dwyer, D. Rindgen, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.

M. Dwyer, D. Rindgen, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.

M. Dwyer, D. Rindgen, J. Fossetta, 2008, Bioorganic & medicinal chemistry letters.

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.

C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.

M. Dwyer, D. Rindgen, D. Lundell, 2007, Bioorganic & medicinal chemistry letters.

Syntheses of 5´-amino-2´,5´-dideoxy-2´,2´-difluorocytidine derivatives as novel anticancer nucleoside analogs

T. Guzi, K. Paruch, M. Dwyer, 2014 .

Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist

M. Billah, M. Dwyer, J. Fossetta, 2007, Journal of Pharmacology and Experimental Therapeutics.

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.

E. Lees, T. Fischmann, W. Seghezzi, 2007, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of Sch 527123 , a Potent Allosteric CXCR 1 / CXCR 2 Antagonist

M. Billah, M. Dwyer, J. Fossetta, 2007 .

Elucidation of the electronic structure of sulfur-containing molybdoenzyme model compounds using magnetic circular dichroism and UV-Visible spectroscopy

M. Dwyer, 1992 .

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

Brian McKittrick, Yaolin Wang, Emma Lees, 2007, Bioorganic & medicinal chemistry letters.

Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.

Tao Ji, William Morris, M Katharine Holloway, 2017, ACS medicinal chemistry letters.

Discovery of potent macrocyclic HCV NS5A inhibitors.

James I. Fells, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.

M. Dwyer, A. Nomeir, R. Mazzola, 2016, Bioorganic & medicinal chemistry letters.

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.

Iodocyclopropanes as versatile intermediates for the synthesis of substituted cyclopropanes

M. Dwyer, S. Martin, 1998 .

Application of AlMe3-mediated amidation reactions to solution phase peptide synthesis

M. Dwyer, C. L. Lynch, S. Martin, 1998 .

Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium(II) Carboxamide Catalysts

S. Liras, M. Dwyer, M. Doyle, 1995 .

Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.

M. Dwyer, J. Baldwin, L. Ozgur, 2006, Bioorganic & medicinal chemistry letters.

Cyclopropane-derived peptidomimetics. Design, synthesis, and evaluation of novel enkephalin analogues.

M. Dwyer, S. F. Martín, K. S. Knight, 2000, The Journal of organic chemistry.

CXCR2 modulators: a patent review (2009 – 2013)

M. Dwyer, Younong Yu, 2014, Expert opinion on therapeutic patents.

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.

M. Dwyer, J. Baldwin, L. Ozgur, 2006, Journal of medicinal chemistry.

The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.

D. Wyss, W. Seghezzi, F. Shanahan, 2014, Bioorganic & medicinal chemistry.

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

W. Seghezzi, F. Shanahan, Ming Liu, 2011, Molecular Cancer Therapeutics.

Synthesis of enantiomerically pure vinylcyclopropanes by SN2′ allylic carboxylate displacements

M. Dwyer, S. Martin, R. K. Hom, 1999 .

Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.

Rebecca T. Ruck, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.

James I. Fells, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.

James I. Fells, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.

S. Stachel, M. Dwyer, Tamara D. Cabalu, 2021, Bioorganic & medicinal chemistry letters.

CXCR2 receptor antagonists: a medicinal chemistry perspective.

M. Dwyer, Younong Yu, 2014, Current topics in medicinal chemistry.

Structure-guided discovery of cyclin-dependent kinase inhibitors.

Emma Lees, David Parry, Kamil Paruch, 2008, Biopolymers.

Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.

J. Uslaner, Sean M. Smith, S. Stachel, 2018, ACS medicinal chemistry letters.

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Discovery of 3,4-diaminocyclobut-3-ene-1,2-dione-based CXCR2 receptor antagonists for the treatment of inflammatory disorders.

M. Dwyer, P. Biju, 2010, Current topics in medicinal chemistry.

A convergent preparation of the CHK1 inhibitor MK-8776 (SCH 900776)

T. Guzi, M. Dwyer, R. Rossman, 2016 .

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.